When a patient presents to their GP with elevated fasting glucose or a diagnosis of pre-diabetes, the standard clinical response focuses on dietary carbohydrate, weight, and medication. Muscle mass is almost never assessed, despite the fact that skeletal muscle is the tissue responsible for the majority of post-meal glucose uptake, and that inadequate muscle mass is one of the most powerful drivers of insulin resistance available. The relationship between sarcopenia and metabolic dysfunction is bidirectional, well-established in the literature, and almost completely absent from routine clinical practice. Adults on the Isle of Man, like those across the UK, deserve to understand how their muscle mass is influencing their metabolic health, because the evidence indicates that rebuilding muscle through resistance exercise is one of the most powerful interventions available for improving metabolic function, independent of weight loss.
How Muscle Mass Drives Glucose Metabolism
Skeletal muscle accounts for approximately 70 to 80 percent of the glucose uptake that occurs following a meal in healthy adults. This uptake occurs through two pathways: insulin-mediated glucose transport via GLUT4 transporter translocation to the muscle cell surface, and insulin-independent glucose uptake during and after exercise through contraction-stimulated GLUT4 translocation. The muscle's capacity for glucose uptake at any given moment is directly proportional to its mass and its mitochondrial density. As muscle mass declines with sarcopenia, the total capacity for post-prandial glucose disposal decreases proportionally, meaning blood glucose remains elevated for longer periods after meals, pancreatic insulin secretion must increase to compensate, and the sustained hyperinsulinaemia contributes to progressive insulin resistance in remaining peripheral tissues.
The quantification of this relationship is striking. Srikanthan and Karlamangla, analysing data from the National Health and Nutrition Examination Survey and published in the Journal of Clinical Endocrinology and Metabolism in 2011, found that each 10 percent decrease in skeletal muscle index, a measure of muscle mass relative to height, was associated with an 11 percent increase in insulin resistance risk and a 12 percent increase in pre-diabetes or diabetes risk. These associations persisted after adjusting for age, sex, ethnicity, physical activity, and body fat, indicating that the relationship between muscle mass and metabolic health is independent of the other variables typically assessed in metabolic risk evaluation.
Sarcopenic Obesity: The Most Dangerous Combination
Sarcopenic obesity, the co-occurrence of low muscle mass with high fat mass in the same individual, represents the most metabolically dangerous body composition phenotype studied in the ageing literature. Research by Stenholm and colleagues published in Clinical Nutrition in 2008 found that sarcopenic obesity was associated with significantly higher risks of cardiovascular disease, metabolic syndrome, functional decline, and mortality compared with either sarcopenia or obesity alone. The combination produces a compounding effect: excess adipose tissue, particularly visceral fat, produces pro-inflammatory cytokines that accelerate muscle protein catabolism, while the reduced muscle mass further impairs glucose disposal, driving hyperglycaemia that promotes further fat deposition.
The prevalence of sarcopenic obesity is rising in line with both ageing demographics and increasing obesity rates. In UK population surveys, estimates suggest that sarcopenic obesity affects between 4 and 12 percent of adults over 60, rising substantially in those over 75. Importantly, because body weight is elevated in this group, the low muscle mass component is masked in standard clinical assessment: a person of healthy weight or above, measured only by BMI, will not have their muscle mass evaluated as a matter of routine. The sarcopenic obesity diagnosis is only revealed by body composition assessment, and it fundamentally changes the appropriate clinical intervention: weight loss without muscle preservation will worsen the muscle:fat ratio, while the correct approach combines targeted resistance exercise to build lean mass with a protein-focused nutrition strategy.
Myokines: The Anti-Inflammatory Signal That Muscle Sends
The metabolic role of skeletal muscle extends beyond glucose disposal. When muscle contracts, it secretes signalling proteins called myokines, of which interleukin-6 from exercising muscle is the most studied. The IL-6 released during muscle contraction, unlike the pathological IL-6 produced by adipose tissue in obesity, has anti-inflammatory effects, stimulating the production of anti-inflammatory cytokines IL-10 and IL-1 receptor antagonist while suppressing TNF-alpha production. Regular muscle contraction through exercise therefore produces a sustained anti-inflammatory effect that counteracts the pro-inflammatory state associated with both obesity and ageing.
Other myokines identified in recent years include irisin, which stimulates the conversion of white adipose tissue to thermogenic beige fat; brain-derived neurotrophic factor produced locally in muscle during contraction, which stimulates neurogenesis and cognitive function; and SPARC, which has anti-tumour properties. This myokine signalling represents a mechanism through which maintaining and exercising muscle mass has benefits throughout the body beyond its direct metabolic effects in the muscle itself. The concept of skeletal muscle as an endocrine organ with systemic regulatory functions is now well-established in the exercise physiology literature, and further reinforces the case for prioritising muscle preservation as a central strategy for systemic health in ageing adults.
Practical Metabolic Health Interventions Through Muscle
The clinical implications of the sarcopenia-metabolic health connection are straightforward. Any adult on the Isle of Man with insulin resistance, pre-diabetes, type 2 diabetes, or metabolic syndrome should be evaluated for sarcopenia alongside the standard metabolic assessment. If muscle mass or strength is below age-appropriate reference values, rebuilding lean mass through supervised resistance exercise and EMS combined with adequate protein intake is a primary intervention for metabolic health improvement, not an optional adjunct. The glycaemic benefits of resistance training in type 2 diabetes are independently demonstrated in multiple randomised controlled trials, with reductions in HbA1c of 0.5 to 1.0 percent achievable through exercise alone, comparable in magnitude to many pharmacological interventions.
At Zhen Wellness on the Isle of Man, the longevity assessment includes metabolic health biomarkers alongside body composition and muscle function measures, specifically because the connection between these variables is so strong and so commonly underaddressed. An adult who attends knowing that their blood glucose control is deteriorating but without understanding that their declining muscle mass is a primary driver of that deterioration is missing the most actionable component of the picture. Providing that understanding, and the structured programme to address it, is what a longevity-focused practice on the Isle of Man is positioned to offer.
- Skeletal muscle handles 70-80% of post-meal glucose uptake; declining muscle mass directly impairs glucose control
- Each 10% decrease in skeletal muscle index raises insulin resistance risk by 11% and diabetes risk by 12% (Srikanthan 2011)
- Sarcopenic obesity (low muscle + high fat) carries higher cardiovascular and mortality risk than either condition alone
- Sarcopenic obesity is masked by normal or high BMI; only body composition assessment reveals the low muscle:fat ratio
- Muscle contraction releases myokines with anti-inflammatory, metabolic, and neuroprotective effects throughout the body
- Resistance training reduces HbA1c by 0.5-1.0% in type 2 diabetes, comparable to pharmacological agents
- Metabolic health assessment should always include muscle mass and function measures, not only glycaemic and lipid markers
Sources
- Srikanthan, P., & Karlamangla, A.S. (2011). Relative muscle mass is inversely associated with insulin resistance and prediabetes. Journal of Clinical Endocrinology and Metabolism, 96(9), 2898-2903.
- DeFronzo, R.A., & Tripathy, D. (2009). Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care, 32(Suppl 2), S157-S163.
- Stenholm, S., et al. (2008). Sarcopenic obesity: definition, epidemiology and clinical features. Clinical Nutrition, 27(5), 693-700.
- Pedersen, B.K. (2013). Muscle as a secretory organ. Comprehensive Physiology, 3(3), 1337-1362.
- Sigal, R.J., et al. (2007). Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes. Annals of Internal Medicine, 147(6), 357-369.